Recent studies have implicated mitochondrial amidoxime-reducing component (mARC), a Mo-dependent enzyme, in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) [64]. Here, CCL7 is linked to metabolic dysfunction-associated steatotic liver disease.